IP Library › Granted Patent US 10,328,141
Granted Patent B2
US 10,328,141 · App. 14/903,118 · Granted Jun 25, 2019

Synthetic vaccines against

Inventors: Peter H. Seeberger (Kleinmachnow, DE); Claney Lebev Pereira (Berlin, DE); Chakkumkal Anish (The Hague, NL); Benjamin Schumann (Berlin, DE)
Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
A61K39/092A61K31/7028A61K47/646C07H15/04G01N33/56944A61K2039/6037A61K2039/627G01N2333/3156G01N2469/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,328,141
App. No.
14/903,118
Granted
Jun 25, 2019
Kind
B2
Abstract

The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.

Claims (103)

1. A saccharide of general formula (I):

wherein A represents —(CH 2 ) o1 —;

o1 represents an integer selected from 1, 2, 3, 4, 5 and 6;

M, N and P represent independently of each other one of the following sugar fragments:

wherein the sugar fragments S1, S2, S3 are connected to each other and to —O-A-SH fragment via O-glycosidic bonds, each sugar fragment S1, S2, and S3 is not more than once present in the general formula (I), sugar fragment Si cannot be simultaneously connected to —O-A-SH and sugar fragment S3, sugar fragment S3 cannot be simultaneously connected to —O-A-SH and sugar fragment S2, and sugar fragment S2 cannot be simultaneously connected to —O-A-SH and sugar fragment S1, and n1, n2 and n3 are integers selected from 0 and 1, wherein at least one of the integers n1, n2 and n3 is 1

and pharmaceutically acceptable salts of these saccharides.

2. A synthesis of the saccharide of the general formula (I):

wherein A represents (CH 2 ) o1;

o1 represents an integer selected from 1, 2, 3, 4, 5 and 6;

M, N and P represent independently of each other one of the following sugar fragments:

wherein the sugar fragments S1, S2, S3 are connected to each other and to —O-A-SH fragment via O-glycosidic bonds, each sugar fragment S1, S2, and S3 is not more than once present in the general formula (I), sugar fragment Si cannot be simultaneously connected to —O-A-SH and sugar fragment S3, sugar fragment S3 cannot be simultaneously connected to —O-A-SH and sugar fragment S2, and sugar fragment S2cannot be simultaneously connected to —O-A-SH and sugar fragment S1, and n1, n2 and n3 are integers selected from 0 and 1, wherein at least one of the integers n1, n2 and n3 is 1

and comprising :

A1) Reacting the compound 2 of the formula:

wherein P 1 -P 3 represent protecting groups,

with the compound 3 of the formula

wherein P 4 represents a protecting group, in order to obtain compound 4 of general formula:

wherein P 1 -P 4 and A are defined as above;

and

performing removal of protecting groups P 1 -P 4 on compound 4 to afford monosaccharide disulfide 5 of general formula:

wherein A is defined as above, and wherein monosaccharide disulfide 5 is further treated with a reducing agent to afford monosaccharide 6 of general formula:

wherein A is defined as above;

or

performing selective deprotection on compound 4 to afford compound 7 of general formula

wherein P 5 is a protecting group and P 1 , P 3 , P 4 and A are defined as above;

or

A2) Reacting compound 8 of general formula

wherein P 6 and P 7 represent protecting groups, with compound 3 to afford compound 9 of general formula

wherein P 6 , P 7 and A are defined as above;

and

performing conversion of the azido group to acetamido group and removal of the protecting groups P 4 , P 6 and P 7 on compound 9 to afford monosaccharide disulfide 10 of general formula:

wherein A is defined as above, and wherein monosaccharide disulfide 10 is further treated with a reducing agent to afford monosaccharide 11 of general formula:

wherein A is defined as above;

or

performing selective deprotection on compound 9 to afford compound 12 of general formula:

wherein P 4 , P 7 and A are defined as above;

or

A3) Reacting compound 13 of general formula

wherein P 8 -P 11 represent protecting groups, with compound 3 to afford compound 14 of general formula:

wherein P 4 , P 8 -P 11 are defined as above; and

performing selective deprotection of compound 14 to afford compound 15 of general formula:

wherein P 4 , P 8 , P 9 , P 11 and A are defined as above; and

B1) Reacting compound 7 with compound 13 to afford compound 16 of general formula:

wherein P 1 , P 3 -P 5 , P 8 -P 11 and A are defined as above; and

performing removal of protecting groups P 1 P 3 -P 5 , P 8 -P 11 on compound 16 to afford disaccharide disulfide 17 of general formula:

wherein A is defined as above and wherein disaccharide disulfide 17 is further treated with a reducing agent to afford disaccharide 18 of general formula:

wherein A is defined as above;

or

performing selective removal of protecting group P 10 on compound 16 to afford compound 19of general formula:

wherein P 1 , P 3 -P 5 , P 8 , P 9 , P 11 and A are defined as above; or

B2) Reacting compound 15 with compound 8 to afford compound 20 of general formula:

wherein P 4 , P 6 -P 9 , P 11 and A are defined as above; and

performing conversion of the azido group to acetamido group and removal of the protecting groups P 4 , P 6 -P 9 , P 11 on compound 20 to afford disaccharide disulfide 21 of general formula:

wherein A is defined as above and wherein disaccharide disulfide 21 is treated with a reducing agent to afford disaccharide 22 of general formula:

wherein A is defined as above;

or

performing selective removal of protecting group P 6 on compound 20 to afford compound 23of general formula:

wherein P 4 , P 7 -P 9 , P 11 and A are defined as above;

or

B3) Reacting compound 12 with compound 2 to afford compound 24 of general formula:

wherein P 1 -P 4 , P 7 and A are defined as above,

and

performing conversion of the azido group to acetamido group and removal of protecting groups P 1 -P 4 and P 7 on compound 24 to afford disaccharide disulfide 25 of general formula:

wherein A is defined as above, and wherein disaccharide disulfide 25 is further treated with a reducing agent to afford disaccharide 26 of general formula:

wherein A is defined as above;

or

performing selective deprotection on compound 24 to afford compound 27 of general formula:

wherein P 12 is a protecting group and P 1 , P 3 , P 4 , P 7 and A are defined as above;

and

C1) Reacting compound 19 with compound 8 to afford compound 28 of general formula:

wherein P 1 , P 3 -P 9 , P 11 and A are defined as above;

and

wherein protecting group P 6 is replaced with protecting group P 13 in order to obtain compound 29 of the following chemical formula:

wherein P 1 , P 3 -P 5 , P 7 -P 9 , P 11 , P 13 and A are defined as above;

and

conversion of compound 29 to trisaccharide disulfide 30 by conversion of the azido group in the acetamido group and cleavage of the protecting group P 1 , P 3 -P 5 , P 7 -P 9 , P 11 , 13 , wherein compound 30 is of general formula:

and wherein A is defined as above;

and

conversion of trisaccharide disulfide 30 to trisaccharide 31 by treatment with a reducing agent, wherein compound 31 is of general formula:

and wherein A is defined as above;

or

C2) Reacting compound 23 with compound 2 to afford compound 32 of general formula:

wherein P 1 -P 4 , P 7 -P 9 , P 11 and A are defined as above;

and

conversion of compound 32 to trisaccharide disulfide 33 by conversion of the azido group in the acetamido group and cleavage of the protecting group P 1 -P 4 , P 7 -P 9 , P 11 , wherein compound 33 is of general formula:

wherein A is defined as above;

and

conversion of trisaccharide disulfide 33 to trisaccharide 34 by treatment with a reducing agent, wherein compound 34 is of general formula:

wherein A is defined as above;

or

C3) Reacting compound 27 with compound 13 to afford compound 35 of general formula:

wherein P 1 , P 3 , P 4 , P 7 -P 11 and A are defined as above;

and

conversion of compound 35 to trisaccharide disulfide 36 by conversion of the azido group in the acetamido group and cleavage of the protecting group P 1 , P 3 , P 4 , P 7 -P 11 wherein compound 36 is of general formula:

wherein A is defined as above;

and

conversion of trisaccharide disulfide 36 to trisaccharide 37 by treatment with a reducing agent, wherein compound 37 is of general formula:

wherein A is defined as above.

3. The synthesis according to claim 2 further comprising:

preparing a salt of the compound of general formula (I) or preparing a lyophilisate of the compound of general formula (I) or of the salt of the compound of general formula (I).

4. The synthesis according to claim 2 , wherein the reactions between compounds 2 and 3, compounds 2 and 12, and compounds 2 and 23 are performed in presence of DMTST and TTBPy in a mixture of non-polar and polar aprotic solvents.

5. The synthesis according to claim 2 , wherein the replacement of protecting group P 6 on compound 28 with protecting group P 13 to obtain compound 29 is performed in two steps, first involving the reaction of compound 28 with hydrazine or a hydrazinium salt in a solvent or a mixture of solvents, and second by treatment of the product obtained after the first step with BnOCH 2 SCy, DMTST and TTBPy in a non-polar solvent.

6. The synthesis according to claim 2 , wherein the cleavage of the protecting groups involves first cleavage of the base-labile protecting groups by treatment with a base in a mixture of polar aprotic and polar protic solvents; and second cleavage of the protecting groups sensitive to hydrogenation by exposure to sodium and ammonia in a mixture of polar protic and polar aprotic solvents.

7. A pharmaceutical composition comprising the saccharide according to claim 1 together with at least one pharmaceutically acceptable cryoprotectant, lyoprotectant, excipient and/or diluent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2016
From: SEEBERGER, PETER H.; PEREIRA, CLANEY LEBEV; ANISH, CHAKKUMKAL; SCHUMANN, BENJAMIN
To: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
Reel/Frame 037644/0346 →
Priority Claims (3)
EP 13175447 · Jul 7, 2013 · regional
EP 13183826 · Sep 10, 2013 · regional
EP 13196568 · Dec 10, 2013 · regional
Continuity (1)
Related Publication 20160346374A1 · Dec 1, 2016